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The matured fruits of Diospyros peregrina are successfully employed by the traditional healers and local people of costal West
Bengal, India for the treatment of diabetes. Present investigation was undertaken to evaluate the role of hydroalcoholic extract of
D. peregrina (HDP) on type 2 diabetes as well as the augmented oxidative stresses associated with it. Oral administration of HDP
at 25, 50 and 100mgkg−1 body weight per day to diabetic rats was found to possess signiﬁcant dose-dependent hypoglycemic
and hypolipidemic activity. The diabetic rats showed lower activities of superoxide dismutase (SOD), catalase (CAT) and reduced
glutathione (GSH) content in hepatic and renal tissues as compared to normal rats. The activities of SOD, CAT and GSH were
found to be increased in extract-treated diabetic rats in selected tissues. The increased level of lipid peroxidation (thiobarbituric
acid reactive substances) in diabetic rats was also found to be reverted back to near normal status in extract-treated groups. Thus
it may be concluded that the HDP may produce its hypoglycemic eﬀect through antioxidant defense mechanism.
1.Introduction
Diabetes mellitus is a chronic metabolic disorder charac-
terized by elevated blood glucose concentration caused by
insulin deﬁciency, often combined with insulin resistance
[1]. By the year 2030, the total number of people worldwide
with diabetes mellitus is projected to reach 366 million
[2]. Type 2 or non-insulin-dependent diabetes mellitus
(NIDDM) accounts for about 90%–95% of all diagnosed
cases of diabetes [3]. Hyperglycemia alone does not cause
diabetic complications. It is rather the detrimental eﬀect
of glucose toxicity due to chronic hyperglycemia mediated
and complicated through augmented oxidative stress [4].
Hyperglycemia increases the production of reactive oxygen
species (ROS) inside the aortic endothelial cells. ROS-
induced activation of protein kinase-C isoforms, increased
formation of glucose-derived advanced glycation end prod-
ucts, increased glucose ﬂux through aldose reductase path-
ways and activation of cytokines are some of the known
biochemical mechanisms of hyperglycemia-induced tissue
and cell damage [5]. Thus, antioxidant therapy in diabetes
may be helpful in relieving symptoms and complications
observed in diabetes patients. Many traditional medicinal
plants that possess substantial quantity of antioxidant com-
ponents have been found to be useful against diabetes
and its related complications [6, 7]. Hence, there is a
huge prospect of development of potential hypoglycemic
agent coupled with antioxidant activity from traditional
medicinal plants to combat diabetes and its complications
[8].
Diospyros peregrina Gurke. (Ebenaceae) is a middle-
sized tree that grows luxuriantly in the plains of costal
region in India. Mature fruits are edible with ethnomedicinal
signiﬁcance as tonic and aphrodisiace [9]. Unripe fruits are
astringent, acrid, bitter and oleaginous [10]. Unripe fruits
are used for the treatment of diarrhea, dysentery, cholera,
m o u t hu l c e ra n di nw o u n d s[ 11]. The matured fruits of
D. peregrina are successfully employed by the traditional
healers and local people of costal West Bengal for the
treatment of diabetes. The mature fruits of D. peregrina
contain substantial quantity of phytopolyphenolics, which
are known for their important antioxidant activity [12, 13].
The present investigation was undertaken to evaluate the
role of hydroalcoholic extract of D. peregrina fruit pulps
(HDPs) in eﬀective management of type 2 diabetes through
antioxidant defense mechanism.2 Evidence-Based Complementary and Alternative Medicine
2. Methods
2.1. Plant Material. Mature fruits of D. peregrina were
collected in the month of July 2006 from the villages of
costal West Bengal, India. The plant was authenticated
by H. J. Chowdhury, Joint Director, Botanical Survey
of India, Shibpur, Howrah, India. A voucher specimen
JU/PT/PC/01/06 was deposited at our laboratory for future
reference.
2.2. Chemicals. Streptozotocin was procured from SISCO
Research Lab, Mumbai, India. Thiobarbituric acid was
purchased from Loba Chemie, Mumbai, India. All chemicals
a n dr e a g e n t su s e dw e r eo fa n a l y t i c a lg r a d e .
2.3. Preparation of Extract. The fruit pulps were dried in
an incubator at 40◦C for 1 week, pulverized in an electrical
grinder and macerated for 48h at room temperature with
800mL of mixture (double distilled water: 99% absolute
alcohol; 30%:70% v/v). The macerate was ﬁltered and
concentrated in vacuo (at 35◦C and 0.8MPa) and ﬁnally
lyophilized to yield HDP (7.5% w/w). The total concentra-
tion of polyphenolics [14] and ﬂavonoids [15] present in this
extract was determined.
2.4. Animals. Three-day-old pups of the Wistar albino rats
were used for this experiment. Pups were kept with the
mother rat in a standard polypropylene cage. Animals were
maintained under standard laboratory conditions oftemper-
ature (20±2◦C), relative humidity (50±15%), 12h light–
darkcycle,standarddiet andwateradlibitum. The principles
of Laboratory Animals Care [16] and the instructions given
by our institutional animal ethical committee (Registration
No: 0367/01/C/CPCSEA) were followed throughout the
experiment.
2.5. Induction of Diabetes. The neonatal-streptozotocin-
diabetic rat model was performed as per the method
described by Portha et al. [17]. Rats were injected intraperi-
toneally with 90mgkg−1 streptozotocin in 0.01M citrate
buﬀer (pH 4.5) [17, 18]. Twelve weeks after the injection
of streptozotocin, the animals exhibiting fasting glucose
levels 140–200mgdL−1 were screened as type 2 diabetic
and neonatal-streptozotocin-diabetic rats resembling type 2
d i a b e t e si nh u m a n s[ 19].
2.6. Experimental Design. Animals were divided into six
groups of six rats each. Group I: normal rats administered
distilled water, 2.0 mLkg−1,o r a l l yd a i l yf o r5d a y s .G r o u p
II: diabetic control rats administered distilled water daily
for 5 days. Group III: diabetic rats administered HDP,
25mgkg−1, orally daily for 5 days. Group IV: diabetic rats
administeredHDP,50mgkg−1,o rall ydail yfo r5da ys.G r oup
V: diabetic rats administered HDP, 100mgkg−1,o r a l l yd a i l y
for 5 days. Group VI: diabetic rats administered standard
drug glibenclamide (1mgkg−1, orally) daily for 5 days.
Fasting blood glucose levels were estimated on Days 0, 1, 3,
5 with the help of single touch glucometer (Ascensia Entrust,
Bayer Health Care, USA). Body weights of experimental rats
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Figure 1: Eﬀect of HDP on fasting plasma glucose level of
neonatal-streptozotocin type 2 diabetic rats. Values are expressed as
mean+SEM(n =6). aP <.01comparedwithnormalcontrolgroup.
∗P <.05comparedwithdiabeticcontrolgroup, ∗∗P <.01compared
with diabetic control group.
were measured on Days 1, 3 and 5. After 5 days of treatment,
all the rats were anaesthetized and sacriﬁced by cervical
dislocation; livers and kidneys were excised and washed
thoroughly to clear oﬀ blood. The tissues were immediately
transferred to ice-cold saline and homogenized in 0.1N Tris-
HCl buﬀer (pH 7.4). These homogenate tissues were used
for the estimation of thiobarbituric acid reactive substances
(TBARSs) [20], reduced glutathione (GSH) [21], superoxide
dismutase (SOD) [22] and catalase (CAT) [23]. Serum lipids
and liver glycogen [24] proﬁles were also estimated.
2.7. Statistical Analysis. Data were statistically calculated by
utilizing one-way ANOVA and expressed as mean±SEM.
followed by Dunnett’s t-test using computerized GraphPad
InStat version 3.05, Graph pad software, USA. The values
were considered signiﬁcant when P <.05.
3. Results
3.1. Polyphenolics and Flavonoids Quantity. The level of total
polyphenolic compounds was found to be 118.24 mg of
pyrocatechol equivalent per gram of dry weight of HDP.Evidence-Based Complementary and Alternative Medicine 3
Table 1: Eﬀect of HDP on serum lipids and liver glycogen levels of type 2 diabetic rats.
Group Cholesterol (mgdl−1) Triglycerides (mgdl−1)L i v e r g l y c o g e n ( m g g −1)
Normal control 76.83±3.34 78.83±3.12 14.17±1.08
Diabetic control 111.17±4.64a 112.67±5.91a 7.45±0.69a
Diabetic+HDP (25mgkg−1) 91.54±6.12∗ 92.17±7.03∗ 12.38±1.01∗
Diabetic+HDP (50mgkg−1) 89.24±4.22∗ 87.67±5.42∗ 13.35±1.21∗∗
Diabetic+HDP (100mgkg−1) 88.33±4.34∗∗ 79.50±4.67∗∗ 13.67±1.12∗∗
Diabetic+Glibenclamide (1mgkg−1) 89.67±3.62∗ 85.50±4.43∗∗ 14.02±1.19∗∗
Data are mean±SE of six animals for each group.
aP <.01 compared with normal control group.
∗P <.05, ∗∗P <.01 compared with diabetic control group.
Liver
Kidney
Normal Diabetic
control
Diabetic +
HDP
(25mg/kg)
Diabetic +
HDP
(50mg/kg)
Diabetic +
HDP
(100mg/kg)
Diabetic +
Glibenclamide
(1mg/kg)
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2
2.25
20.5
T
B
A
R
S
(
m
M
/
1
0
0
g
t
i
s
s
u
e
)
a
a
∗
∗
∗
∗∗
∗ ∗∗
∗
Figure 2: Eﬀect of HDP on TBARS of hepatic and renal tissues of
type 2 diabetic rats. Data are mean±SE of six animals for each
group. aP <. 0 1c o m p a r e dw i t hn o r m a lc o n t r o lg r o u p .∗P <.05
compared with diabetic control group, ∗∗P <.01 compared with
diabetic control group.
Total ﬂavonoids content was found to be 84.45mg of
quercetin equivalent per gram of HDP.
3.2. Blood Glucose Status. A signiﬁcant diﬀerence was
observed between normal and type 2 diabetic rats (P <.01)
in fasting blood glucose level. HDP at the doses of 25, 50 and
100mgkg−1 body weight signiﬁcantly lowered fasting blood
glucose level of type 2 diabetic and exhibited maximum
reduction of 13.98 (P <.05), 23.89 (P <.01) and 32.05%
(P <.01) on Day 5, respectively. The results were com-
pared with standard oral hypoglycemic agent glibenclamide
(1mgkg−1),whichexhibitedmaximumreductionof36.12%
(P <.01) on Day 5 (Figure 1).
3.3. Blood Lipid Status. Signiﬁcant increase (P <.01) in
cholesterol and triglycerides levels was observed in diabetic
rats when compared with normal control groups. Treatment
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Figure 3: Eﬀect of HDP on GSH of hepatic and renal tissues of type
2 diabetic rats. Data are mean±SE of six animals for each group. aP
<.01comparedwithnormalcontrolgroup. ∗P <.05comparedwith
diabetic control group, ∗∗P <.01 compared with diabetic control
group.
with HDP signiﬁcantly lowered the levels of cholesterol and
triglyceride in a dose-dependent manner when compared
with diabetic control group. The hypolipidemic eﬀect is
more at the dose of 100mgkg−1 and results are comparable
tothatofstandarddrugglibenclamide.Asigniﬁcantdecrease
(P <.01) in the level of liver glycogen was observed in
diabetic rats when compared with normal control groups
(Table 1).
3.4. Liver Glycogen and Body Weight Status. Oral adminis-
tration of HDP at the selected doses signiﬁcantly increases
liver glycogen level to its normal level and the result is
comparabletothatofstandarddrugglibenclamide (Table 1).4 Evidence-Based Complementary and Alternative Medicine
Table 2: Eﬀect of HDP fruit on body weight proﬁle of type 2 diabetic rats.
Group
Body weight proﬁle (g)
Day 1 Day 3 Day 5
Normal control 164.17±3.01 167.50±2.81 168.33±2.11
Diabetic control 137.50±4.96 135.83±4.36 135.50±3.99
Diabetic+HDP (25mgkg−1) 142.5±3.09 143.33±2.79 144.17±2.82
Diabetic+HDP (50mgkg−1) 140.00±5.77 143.33±6.28 145.83±6.38
Diabetic+HDP (100mgkg−1) 141.67±4.60 140.83±4.55 139.50±5.05
Diabetic+Glibenclamide (1mgkg−1) 140.83±6.23 144.17±6.11 147.50±6.42
Data are mean±SE of six animals for each group.
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Figure 4: Eﬀect of HDP on SOD of hepatic and renal tissues of type
2 diabetic rats. Data are mean±SE of six animals for each group. aP
<.01comparedwithnormalcontrolgroup. ∗P <.05comparedwith
diabetic control group, ∗∗P <.01 compared with diabetic control
group.
HDP treatment also improved body weight proﬁle (statis-
tically insigniﬁcant) in type 2 diabetic rats with respect to
diabetic control group (Table 2).
3.5. Antioxidant Status. The antioxidant eﬀect of the HDP
on tissue antioxidant markers was studied. The type 2
diabetic rats showed a signiﬁcant increase in TBARS in
hepatic and renal tissues (P <.01). Oral administration of
HDP reduced these to normal level (Figure 2). There was
a signiﬁcant reduction (P <.01) in GSH in diabetic rats.
HDP administration to diabetic rats signiﬁcantly increased
liver and kidney GSH to near normal value (Figure 3). The
decreased levels (P <.01) of SOD and CAT in diabetic rats
w e r ef o u n dt ob er e v e r t e db a c kt on e a rn o r m a ls t a t u sa f t e r
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Figure 5: Eﬀect of HDP on CAT of hepatic and renal tissues of type
2 diabetic rats. Data are mean±SE of six animals for each group. aP
<.01comparedwithnormalcontrolgroup. ∗P <.05comparedwith
diabetic control group, ∗∗P <.01 compared with diabetic control
group.
thetreatmentofHDP(Figures4and5).TheHDPwasfound
to possess antioxidant eﬀect in a dose-dependent manner.
4. Discussion
Whenratsareinjectedwithstreptozotocinduringtheneona-
tal period, it resembles human type 2 diabetes mellitus with
respect to abnormalities in insulin secretory responses [25].
In this model, mild hyperglycemia appears between 2 and 3
months of life, together with a partial deﬁciency in insulin
[26]. In the present study, diabetes control rats exhibited
signiﬁcantly elevated fasting blood glucose, cholesterol and
triglyceride levels as compared with normal control rats.
Treatment with HDP signiﬁcantly reduced fasting blood glu-
cose and lipid levels. Maintenance of blood glucose and lipidEvidence-Based Complementary and Alternative Medicine 5
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Figure 6: Multimodal therapeutic approach of HDP to counteract
with diabetic hyperglycemia and free radical mediated pathogene-
sis.
proﬁle with extract-treated rats vindicates the eﬀectiveness
of the extract against experimental type 2 diabetic rats. The
signiﬁcant control of plasma lipid levels suggests that the
extractmayproduceitsactionbyimprovinginsulinsecretion
[27]. Type 2 diabetic rats exhibited signiﬁcantly lower level
of liver glycogen level, which was signiﬁcantly reverted back
near to the normal status in HDP-treated diabetic groups,
may be due to reactivation of the glycogen synthase system
by improving insulin secretion. Diabetes is associated with
weight loss. The reversal of weight loss in extract-treated dia-
betic group indicates that the restorative eﬀect of HDP may
bebythereversalofgluconeogenesisandglycogenolysis[28].
An increase in hepatic and renal TBARS is an index
of enhanced lipid peroxidation in diabetes, which may be
due to enhance production or decrease destruction of ROS
[27]. Increased TBARS in type 2 diabetic rats signiﬁcantly
lower in both the tissues on HDP treatment. Increased lipid
peroxidation in diabetes can be due to enhanced oxidative
stress in the cells as a result of depletion of antioxidant
scavenger system. GSH is a major endogenous antioxidant,
which counteracts free radical-mediated damage. Depletion
of liver and kidney GSH levels represents enhanced oxidative
stress[28].OraladministrationofHDPsigniﬁcantlyelevated
GSH level in selected tissues. SOD is an antioxidant enzyme,
which reduces superoxide radicals to water and molecular
oxygen while CAT reduces hydrogenperoxide [29]. Dimin-
ishedactivityoftheseantioxidantenzymesresultelevationof
ROS and ROS-mediated cell destruction. Reduced activities
of SOD and CAT in liver and kidney were observed in
diabetic rats and these were reverted to near normal status
on extract treatment.
Present investigation showed that the HDP possesses
considerable hypoglycemic and hypolipidemic activity in
type 2 diabetic rats. The HDP also exhibited a profound
antioxidant eﬀect in diabetic rats. The multimodal thera-
peutic approach of HDP has been represented with the help
of hypothetical diagram (Figure 6). The antioxidant defense
system represents a complex network with interactions,
synergy and speciﬁc tasks for a given antioxidant [30,
31]. Recent studies showed that majority of the plasma
antioxidants are depleted in type 2 diabetes [32]. The
depletion of antioxidants in the diabetic condition is a major
cause of diabetes-related complications and onset of other
disease conditions [33, 34]. Present therapeutic strategies
typically attempt to relieve the clinical manifestation of
diabetes and its complications [35]. The major challenge
in diabetes research is to deﬁne not only the cause—eﬀect
relationship between various risk factors and complications,
but also to comprehend the eﬀects of therapeutic agents that
are beneﬁcial in the management of diabetic complications
[36]. Nevertheless, the justiﬁcation for the therapeutic use
of antioxidants in cases of diabetes is emerging fast [37].
The quantitative estimation of total polyphenolics and
ﬂavonoids conﬁrmed that the HDP contains substantial
quantity of polyphenolics and ﬂavonoids, which are the
known antioxidant from plant sources [38]. Polyphenolics
have also been reported to contribute hypoglycemic activity
[39, 40]. So, the polyphenolics-enriched fruits of D. pere-
grina may contribute in eﬀective diabetes management in
future.
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